Cytochrome P450 pharmacogenetics and cancer (original) (raw)

References

• Agundez JA . (2004). Curr Drug Metab 5: 211–224.
• Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L et al. (2003). Mol Pharmacol 64: 659–669.
• Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M . (2002). Mol Pharmacol 61: 586–594.
• Aklillu E, Ovrebo S, Botnen IV, Otter C, Ingelman-Sundberg M . (2005). Cancer Res 65: 5105–5111.
• Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M . (1996). J Pharmacol Exp Ther 278: 441–446.
• Ariyoshi N, Miyamoto M, Umetsu Y, Kunitoh H, Dosaka-Akita H, Sawamura Y et al. (2002). Cancer Epidemiol Biomarkers Prev 11: 890–894.
• Bournique B, Lemarie A . (2002). Drug Metab Dispos 30: 1149–1152.
• Buters J, Quintanilla-Martinez L, Schober W, Soballa VJ, Hintermair J, Wolff T et al. (2003). Carcinogenesis 24: 327–334.
• Buters JT, Sakai S, Richter T, Pineau T, Alexander DL, Savas U et al. (1999). Proc Natl Acad Sci USA 96: 1977–1982.
• Chen JK, Capdevila J, Harris RC . (2001). Mol Cell Biol 21: 6322–6331.
• Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y et al. (2003). Oncogene 22: 7316–7339.
• Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM . (2002). Drug Metab Dispos 30: 869–874.
• Dachs GU, Tupper J, Tozer GM . (2005). Anticancer Drugs 16: 349–359.
• Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al. (2001). Pharmacogenetics 11: 597–607.
• Daigo S, Takahashi Y, Fujieda M, Ariyoshi N, Yamazaki H, Koizumi W et al. (2002). Pharmacogenetics 12: 299–306.
• Dally H, Edler L, Jager B, Schmezer P, Spiegelhalder B, Dienemann H et al. (2003). Pharmacogenetics 13: 607–618.
• DeMichele A, Aplenc R, Botbyl J, Colligan T, Wray L, Klein-Cabral M et al. (2005). J Clin Oncol 23: 5552–5559.
• Desta Z, Zhao X, Shin JG, Flockhart DA . (2002). Clin Pharmacokinet 41: 913–958.
• Dhaini HR, Thomas DG, Giordano TJ, Johnson TD, Biermann JS, Leu K et al. (2003). J Clin Oncol 21: 2481–2485.
• Downie D, McFadyen MC, Rooney PH, Cruickshank ME, Parkin DE, Miller ID et al. (2005). Clin Cancer Res 11: 7369–7375.
• Ekins S, Vandenbranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV et al. (1998). J Pharmacol Exp Ther 286: 1253–1259.
• Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG et al. (2004). Clin Pharmacol Ther 75: 448–454.
• Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J et al. (1999). J Clin Oncol 17: 1516–1525.
• Gambier N, Batt AM, Marie B, Pfister M, Siest G, Visvikis-Siest S . (2005). Pharmacogenomics J 5: 271–275.
• Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V et al. (1999). Pharmacogenetics 9: 295–306.
• Gharavi N, El-Kadi AO . (2004). Curr Drug Metab 5: 203–210.
• Gibson P, Gill JH, Khan PA, Seargent JM, Martin SW, Batman PA et al. (2003). Mol Cancer Ther 2: 527–534.
• Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J et al. (2002). J Clin Oncol 20: 3683–3690.
• Gonzalez FJ . (2003). Drug Metab Rev 35: 319–335.
• Goodwin B, Moore LB, Stoltz CM, McKee DD, Kliewer SA . (2001). Mol Pharmacol 60: 427–431.
• Goria-Gatti L, Iannone A, Tomasi A, Poli G, Albano E . (1992). Carcinogenesis 13: 799–805.
• Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K et al. (2005). Clin Cancer Res 11: 4430–4436.
• Guengerich FP, Parikh A, Turesky RJ, Josephy PD . (1999). Mutat Res 428: 115–124.
• Han XM, Ouyang DS, Chen XP, Shu Y, Jiang CH, Tan ZR et al. (2002). Br J Clin Pharmacol 54: 540–543.
• Hankinson O . (1995). Annu Rev Pharmacol Toxicol 35: 307–340.
• Harris JW, Katki A, Anderson LW, Chmurny GN, Paukstelis JV, Collins JM . (1994). J Med Chem 37: 706–709.
• Hayashi S, Watanabe J, Kawajiri K . (1991). J Biochem (Tokyo) 110: 559–565.
• Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K et al. (2005). Clin Cancer Res 11: 8097–8104.
• Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL et al. (2004). Pharmacogenetics 14: 225–238.
• Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH . (2000). Clin Cancer Res 6: 1255–1258.
• Huang Z, Raychowdhury MK, Waxman DJ . (2000a). Cancer Gene Ther 7: 1034–1042.
• Huang Z, Roy P, Waxman DJ . (2000b). Biochem Pharmacol 59: 961–972.
• Ingelman-Sundberg M . (2004a). Naunyn-Schmiedeberg's Arch Pharmacol 369: 89–104.
• Ingelman-Sundberg M . (2004b). Trends Pharmacol Sci 25: 193–200.
• Ingelman-Sundberg M . (2005). Pharmacogenomics J 5: 6–13.
• Ingelman-Sundberg M, Rodriguez-Antona C . (2005). Philos Trans R Soc Lond B Biol Sci 360: 1563–1570.
• Jacobson PA, Green K, Birnbaum A, Remmel RP . (2002). Cancer Chemother Pharmacol 49: 461–467.
• Jiang JG, Chen CL, Card JW, Yang S, Chen JX, Fu XN et al. (2005). Cancer Res 65: 4707–4715.
• Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH et al. (2005). J Natl Cancer Inst 97: 30–39.
• Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M . (1993). Proc Natl Acad Sci USA 90: 11825–11829.
• Jordan VC, Collins MM, Rowsby L, Prestwich G . (1977). J Endocrinol 76: 305–316.
• Kaijser GP, Korst A, Beijnen JH, Bult A, Underberg WJ . (1993). Anticancer Res 13: 1311–1324.
• Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB et al. (2002). J Clin Oncol 20: 2805–2811.
• Karlgren M, Gomez A, Stark K, Svärd J, Rodriguez-Antona C, Oliw E et al. (submitted).
• Karlgren M, Miura S, Ingelman-Sundberg M . (2005). Toxicol Appl Pharmacol 207: 57–61.
• Kirchheiner J, Brockmoller J . (2005). Clin Pharmacol Ther 77: 1–16.
• Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M et al. (2005). Pharmacogenet Genomics 15: 861–873.
• Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T . (2000). Drug Metab Dispos 28: 1457–1463.
• Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. (2001). Nat Genet 27: 383–391.
• Kumarakulasingham M, Rooney PH, Dundas SR, Telfer C, Melvin WT, Curran S et al. (2005). Clin Cancer Res 11: 3758–3765.
• Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T . (1997). Eur J Biochem 247: 625–634.
• Landi S, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A, Guino E et al. (2005). Pharmacogenet Genomics 15: 535–546.
• Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U et al. (2001). Pharmacogenetics 11: 399–415.
• Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M et al. (2004). J Pharmacol Exp Ther 311: 34–43.
• Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E et al. (2003). Pharmacogenetics 13: 461–472.
• Leong CO, Gaskell M, Martin EA, Heydon RT, Farmer PB, Bibby MC et al. (2003). Br J Cancer 88: 470–477.
• Li AP, Kaminski DL, Rasmussen A . (1995). Toxicology 104: 1–8.
• Libby RT, Smith RS, Savinova OV, Zabaleta A, Martin JE, Gonzalez FJ et al. (2003). Science 299: 1578–1581.
• Lohr M, Hoffmeyer A, Kroger J, Freund M, Hain J, Holle A et al. (2001). Lancet 357: 1591–1592.
• Malaiyandi V, Sellers EM, Tyndale RF . (2005). Clin Pharmacol Ther 77: 145–158.
• Martinez C, Garcia-Martin E, Blanco G, Gamito FJ, Ladero JM, Agundez JA . (2005). Br J Clin Pharmacol 59: 62–69.
• Masson LF, Sharp L, Cotton SC, Little J . (2005). Am J Epidemiol 161: 901–915.
• Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T et al. (2004). J Natl Cancer Inst 96: 1585–1592.
• Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A . (2002). J Natl Cancer Inst 94: 1247–1249.
• McFadyen MC, Breeman S, Payne S, Stirk C, Miller ID, Melvin WT et al. (1999). J Histochem Cytochem 47: 1457–1464.
• McFadyen MC, Cruickshank ME, Miller ID, McLeod HL, Melvin WT, Haites NE et al. (2001a). Br J Cancer 85: 242–246.
• McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J, Murray GI . (2001b). Biochem Pharmacol 62: 207–212.
• McFadyen MC, Melvin WT, Murray GI . (2004). Mol Cancer Ther 3: 363–371.
• Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF . (2003). Neuropharmacology 45: 122–132.
• Miyoshi Y, Ando A, Takamura Y, Taguchi T, Tamaki Y, Noguchi S . (2002). Int J Cancer 97: 129–132.
• Miyoshi Y, Taguchi T, Kim SJ, Tamaki Y, Noguchi S . (2005). Breast Cancer 12: 11–15.
• Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD et al. (1997). Cancer Res 57: 3026–3031.
• Nakajima M, Fujiki Y, Kyo S, Kanaya T, Nakamura M, Maida Y et al. (2005). J Clin Pharmacol 45: 674–682.
• Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H et al. (2001). Clin Pharmacol Ther 69: 72–78.
• Nebert DW, Dalton TP, Okey AB, Gonzalez FJ . (2004). J Biol Chem 279: 23847–23850.
• Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW . (2004). Pharmacogenetics 14: 1–18.
• Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ . (2003). Clin Pharmacol Ther 74: 380–387.
• Oscarson M . (2001). Drug Metab Dispos 29: 91–95.
• Oscarson M, McLellan RA, Gullsten H, Yue QY, Lang MA, Bernal ML et al. (1999). FEBS Lett 448: 105–110.
• Oyama T, Kagawa N, Kunugita N, Kitagawa K, Ogawa M, Yamaguchi T et al. (2004). Front Biosci 9: 1967–1976.
• Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L et al. (2000). Pharmacogenetics 10: 373–388.
• Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA et al. (1999). Cancer Epidemiol Biomarkers Prev 8: 901–905.
• Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T et al. (2002). Br J Cancer 86: 774–778.
• Pozzi A, Macias-Perez I, Abair T, Wei S, Su Y, Zent R et al. (2005). J Biol Chem 280: 27138–27146.
• Rae JM, Soukhova NV, Flockhart DA, Desta Z . (2002). Drug Metab Dispos 30: 525–530.
• Rasmussen BB, Brix TH, Kyvik KO, Brosen K . (2002). Pharmacogenetics 12: 473–478.
• Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB . (1998). J Natl Cancer Inst 90: 1225–1229.
• Riddick DS, Lee C, Ramji S, Chinje EC, Cowen RL, Williams KJ et al. (2005). Drug Metab Dispos 33: 1083–1096.
• Rieger MA, Ebner R, Bell DR, Kiessling A, Rohayem J, Schmitz M et al. (2004). Cancer Res 64: 2357–2364.
• Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL . (2001). J Pharmacol Exp Ther 296: 537–541.
• Rodriguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M . (2005). Biochem Biophys Res Commun 338: 299–305.
• Rooseboom M, Commandeur JN, Vermeulen NP . (2004). Pharmacol Rev 56: 53–102.
• Roy P, Waxman DJ . (2005). Toxicol In Vitro (in press).
• Sachse C, Brockmoller J, Bauer S, Roots I . (1999). Br J Clin Pharmacol 47: 445–449.
• Salmons B, Lohr M, Gunzburg WH . (2003). J Gastroenterol 38(Suppl 15): 78–84.
• Savas U, Hsu MH, Griffin KJ, Bell DR, Johnson EF . (2005). Arch Biochem Biophys 436: 377–385.
• Sim SC, Edwards RJ, Boobis AR, Ingelman-Sundberg M . (2005b). Pharmacogenet Genomics 15: 625–631.
• Sim SC, Risinger C, Dahl M-L, Aklillu E, Christensen M, Bertilsson L et al. (2005a). Clin Pharm Ther (in press).
• Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM et al. (2002). Pharmacogenetics 12: 355–366.
• Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE et al. (2004). Arthritis Rheum 50: 2202–2210.
• Tanaka T, Tanimoto K, Otani K, Satoh K, Ohtaki M, Yoshida K et al. (2004). Int J Cancer 111: 617–626.
• Taniguchi R, Kumai T, Matsumoto N, Watanabe M, Kamio K, Suzuki S et al. (2005). J Pharmacol Sci 97: 83–90.
• Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL . (2003). Br J Cancer 88: 928–932.
• Tayeb MT, Clark C, Sharp L, Haites NE, Rooney PH, Murray GI et al. (2002). Oncol Rep 9: 653–655.
• Timm R, Kaiser R, Lotsch J, Heider U, Sezer O, Weisz K et al. (2005). Pharmacogenomics J 5: 365–373.
• Tokizane T, Shiina H, Igawa M, Enokida H, Urakami S, Kawakami T et al. (2005). Clin Cancer Res 11: 5793–5801.
• Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M et al. (2004). Biochem Biophys Res Commun 319: 1322–1326.
• Vineis P . (2002). Toxicology 181–182: 457–462.
• Wang H, Faucette S, Sueyoshi T, Moore R, Ferguson S, Negishi M et al. (2003). J Biol Chem 278: 14146–14152.
• Wang J, Pitarque M, Ingelman-Sundberg M . (2006). Biochem Biophys Res Commun 340: 491–497.
• Wang J, Sönnerborg A, Rane A, Josephson F, Lundgren S, Ståhle L et al. (2005). Pharmacogenet Genomics (in press).
• Westlind-Johnsson A, Bernhard Hauns D, Hermann R, Huennemeyer A, Lahu G, Nassr N et al. (2006). Clin Pharm Ther (in press).
• Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K et al. (2002). Drug Metab Dispos 30: 883–891.
• Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M et al. (2003). Pharmacogenomics J 3: 53–61.
• Yamamoto N, Tamura T, Murakami H, Shimoyama T, Nokihara H, Ueda Y et al. (2005). J Clin Oncol 23: 1061–1069.
• Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U et al. (2002). Biochem Biophys Res Commun 299: 25–28.
• Yengi LG, Xiang Q, Pan J, Scatina J, Kao J, Ball SE et al. (2003). Anal Biochem 316: 103–110.
• Yu AM, Fukamachi K, Krausz KW, Cheung C, Gonzalez FJ . (2005). Endocrinology 146: 2911–2919.

Download references